Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-26T20:31:40.957Z Has data issue: false hasContentIssue false

Attention on Infection Following Transcatheter Aortic Valve Implantation

Published online by Cambridge University Press:  30 August 2016

Tian-Yuan Xiong
Affiliation:
Department of Cardiology, West China Hospital, Sichuan University, China.
Mao Chen*
Affiliation:
Department of Cardiology, West China Hospital, Sichuan University, China.
*
Address correspondence to Mao Chen, MD, PhD, Department of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, 610041, PR China (hmaochen@vip.sina.com).
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved 

To the Editor—We have read with interest the study by Shi et alReference Shi, Wijeysundera, Fremes and Simor 1 on the incidence and risk factors for infection following transcatheter aortic valve implantation (TAVI). In their report, 35 of 253 patients had infections during the 30 days after the procedure; chronic obstructive pulmonary disease, postprocedural hemorrhage, and procedure-related stroke were identified as variables associated with the development of infection. Although infection has been recognized as one of the most common complications after surgery, its incidence, etiology, and impact following TAVI are not well defined yet. This study, with clear classification of infection types and determination of risk factors, certainly sheds some light on our understanding of this less discussed complication.

Compared with issues such as paravalvular leak, conduction disturbances, or stroke after TAVI, infections seem to be somewhat neglected. Although TAVI is minimally invasive, TAVI candidates usually have predisposing factors for infection, including age; poor pulmonary, renal, and immune function; diabetes mellitus; and need for ventilation and central venous access. Chronic obstructive pulmonary disease was associated with post-TAVI infection in both their univariate and multivariate analyses. In our group’s previous systematic review,Reference Xiong, Liao and Zhao 2 infection/sepsis was the most common cause of death both within and beyond 30 days of TAVI in the pooled analysis. In this study,Reference Shi, Wijeysundera, Fremes and Simor 1 the authors found 8 (22.9%) of those who developed a post-TAVI infection died whereas only 4 (1.8%) of those patients who did not have an infection died (P<.001). Moreover, Tirado-Conte et alReference Tirado-Conte, Freitas-Ferraz and Nombela-Franco 3 also recently contributed research on this issue. During a median follow-up of 21 months, 51 of 303 patients experienced in-hospital infections after TAVI, with respiratory and urinary tract infections being most frequent. Patients with infections also had increased mortality during follow-up, as well as a longer hospital stay and higher readmission rate. These findings altogether demonstrate that infections play a major adverse role in postprocedural management of TAVI recipients.

Respiratory and urinary tract infections were the most frequent type of infections in this study,Reference Shi, Wijeysundera, Fremes and Simor 1 whereas postprocedural hemorrhage requiring transfusion was found to be significantly associated with an increased infection risk. Some of these risk factors are potentially modifiable and emphasize the importance of implementing a standardized postprocedural protocol to offer our patients a quick and smooth recovery. Two recently published articlesReference Lauck, Wood and Baumbusch 4 , Reference Sola, Ramm and Kolarczyk 5 have recommended early removal of Foley catheters and other hemodynamic lines if possible. Expedited transfer from the critical care area to a cardiac step-down unit and criteria-driven early discharge were also encouraged in suitable patients. Theoretically, infections can be expected to decrease once predisposing factors are modified by those enhanced recovery pathways. However, future randomized trials are needed to verify whether these proposed measures can lower infection rates or not.

ACKNOWLEDGMENTS

Financial support. None reported.

Potential conflicts of interest. Both authors report no conflicts of interest relevant to this article.

References

REFERENCES

1. Shi, Y, Wijeysundera, HC, Fremes, SE, Simor, AE. Incidence and risk factors for infection following transcatheter aortic valve implantation [published online June 20, 2016]. Infect Control Hosp Epidemiol 2016:14.Google Scholar
2. Xiong, T-Y, Liao, Y-B, Zhao, Z-G, et al. Causes of death following transcatheter aortic valve replacement: a systematic review and meta-analysis. J Am Heart Assoc 2015;4:e002096.Google Scholar
3. Tirado-Conte, G, Freitas-Ferraz, AB, Nombela-Franco, L, et al. Incidence, causes, and impact of in-hospital infections after transcatheter aortic valve implantation. Am J Cardiol 2016;118:403409.CrossRefGoogle ScholarPubMed
4. Lauck, SB, Wood, DA, Baumbusch, J, et al. Vancouver transcatheter aortic valve replacement clinical pathway: minimalist approach, standardized care, and discharge criteria to reduce length of stay. Circ Cardiovasc Qual Outcomes 2016;9:312321.Google Scholar
5. Sola, M, Ramm, CJ, Kolarczyk, LM, et al. Application of a multidisciplinary enhanced recovery after surgery pathway to improve patient outcomes after transcatheter aortic valve implantation. Am J Cardiol 2016;118:418423.Google Scholar